i-CR体外药敏筛选技术平台，开拓肿瘤新药开发新思路

2018-10-29 智康 MedSci原创

利用i-CR?体系发掘多种药物分子的协同?应，寻找新适应症，为肿瘤药物研发注入新鲜血液

目前，精准医疗已成为肿瘤治疗的趋势，但对肿瘤患者来说，如何精准选择合适的抗肿瘤药物是个难题；而对肿瘤药物研发公司来说，抗肿瘤新药研发周期长，特别是缺乏贴近与临床药效的评估手段。北京智康博药肿瘤医学研究有限公司是一家专注于肿瘤?化精准医疗服务和抗肿瘤药物研发的创新型生物科技公司。近日，该公司林艺海总经理接受了丁香园的采访，介绍了其公司自主研发的i-CRTM体外药敏?选技术平台及其在抗肿瘤新药研发中的重要作用。i-CRTM体系是更加接近肿瘤患者自身状态的高通量药物筛选平台，该技术原理是从患者处获取新鲜的肿瘤组织，将其变成可大量增殖的原代肿瘤细胞，并利用高内涵荧光显微系统来观察药物对细胞的影响，以此作为患者“替身”测试抗肿瘤药物的效果。图

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1950464, encodeId=949a195046460, content=<a href='/topic/show?id=b53382961a2' target=_blank style='color:#2F92EE;'>#肿瘤新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82961, encryptionId=b53382961a2, topicName=肿瘤新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sat Dec 15 18:11:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019340, encodeId=297720193401d, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Jun 16 15:11:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655594, encodeId=7c15165559497, content=<a href='/topic/show?id=09635863424' target=_blank style='color:#2F92EE;'>#新药开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58634, encryptionId=09635863424, topicName=新药开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Mar 05 09:11:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584410, encodeId=97df158441049, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Oct 31 02:11:00 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
2018-12-15 july_975

#肿瘤新药#

31 0
[GetPortalCommentsPageByObjectIdResponse(id=1950464, encodeId=949a195046460, content=<a href='/topic/show?id=b53382961a2' target=_blank style='color:#2F92EE;'>#肿瘤新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82961, encryptionId=b53382961a2, topicName=肿瘤新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sat Dec 15 18:11:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019340, encodeId=297720193401d, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Jun 16 15:11:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655594, encodeId=7c15165559497, content=<a href='/topic/show?id=09635863424' target=_blank style='color:#2F92EE;'>#新药开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58634, encryptionId=09635863424, topicName=新药开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Mar 05 09:11:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584410, encodeId=97df158441049, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Oct 31 02:11:00 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
2019-06-16 晓辰

#新思路#

22 0
[GetPortalCommentsPageByObjectIdResponse(id=1950464, encodeId=949a195046460, content=<a href='/topic/show?id=b53382961a2' target=_blank style='color:#2F92EE;'>#肿瘤新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82961, encryptionId=b53382961a2, topicName=肿瘤新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sat Dec 15 18:11:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019340, encodeId=297720193401d, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Jun 16 15:11:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655594, encodeId=7c15165559497, content=<a href='/topic/show?id=09635863424' target=_blank style='color:#2F92EE;'>#新药开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58634, encryptionId=09635863424, topicName=新药开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Mar 05 09:11:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584410, encodeId=97df158441049, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Oct 31 02:11:00 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
2019-03-05 智智灵药

#新药开发#

43 0
[GetPortalCommentsPageByObjectIdResponse(id=1950464, encodeId=949a195046460, content=<a href='/topic/show?id=b53382961a2' target=_blank style='color:#2F92EE;'>#肿瘤新药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82961, encryptionId=b53382961a2, topicName=肿瘤新药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Sat Dec 15 18:11:00 CST 2018, time=2018-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019340, encodeId=297720193401d, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Jun 16 15:11:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655594, encodeId=7c15165559497, content=<a href='/topic/show?id=09635863424' target=_blank style='color:#2F92EE;'>#新药开发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58634, encryptionId=09635863424, topicName=新药开发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Mar 05 09:11:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584410, encodeId=97df158441049, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Oct 31 02:11:00 CST 2018, time=2018-10-31, status=1, ipAttribution=)]
2018-10-31 ms6747015003810650

#筛选#

36 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

医学知识

i-CR体外药敏筛选技术平台，开拓肿瘤新药开发新思路

相关资讯

科室

工具

服务